MedPath
Found 9 clinical trials|View Analysis
Sort by:

Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

Phase 2
Recruiting
Conditions
Esophagus Squamous Cell Carcinoma
Interventions
First Posted Date
2023-05-18
Last Posted Date
2023-05-18
Lead Sponsor
AIPING ZHOU
Target Recruit Count
30
Registration Number
NCT05865132
Locations
🇨🇳

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

Phase 2
Not yet recruiting
Conditions
Stage IV Esophagus Squamous Cell Carcinoma
Interventions
First Posted Date
2022-04-11
Last Posted Date
2022-04-11
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
80
Registration Number
NCT05322499
Locations
🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

Phase 2
Recruiting
Conditions
Gastroesophageal Junction Adenocarcinoma
Esophagus Squamous Cell Carcinoma
Esophagus Adenocarcinoma
Interventions
First Posted Date
2019-07-15
Last Posted Date
2021-11-04
Lead Sponsor
Dallas VA Medical Center
Target Recruit Count
78
Registration Number
NCT04018872
Locations
🇺🇸

Dallas VA Medical Center, Dallas, Texas, United States

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Phase 3
Recruiting
Conditions
Clinical Stage I Esophageal Adenocarcinoma AJCC v8
Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage II Esophageal Adenocarcinoma AJCC v8
Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8
Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8
Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions
Drug: Carboplatin
Procedure: Esophagectomy
Drug: Paclitaxel
Radiation: Intensity-Modulated Radiation Therapy
Radiation: Proton Beam Radiation Therapy
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: FOLFOX regimen
Drug: CAPOX regimen
Drug: Docetaxel
Drug: 5FU
First Posted Date
2019-01-14
Last Posted Date
2024-11-27
Lead Sponsor
NRG Oncology
Target Recruit Count
300
Registration Number
NCT03801876
Locations
🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

🇺🇸

University Hospitals Sharon Health Center, Wadsworth, Ohio, United States

🇺🇸

Corewell Health Dearborn Hospital, Dearborn, Michigan, United States

and more 87 locations

Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy

Active, not recruiting
Conditions
Squamous Cell Carcinoma of the Head and Neck
Cancer
Metastatic Cancer
Anal Canal Squamous Cell Carcinoma
Esophagus Squamous Cell Carcinoma
First Posted Date
2018-10-19
Last Posted Date
2024-03-12
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
39
Registration Number
NCT03712566
Locations
🇨🇦

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Early Detection of Head and Neck Superficial Squamous Cell Carcinoma in Patients With Esophagus Squamous Cell Carcinoma

Not Applicable
Conditions
Optical Enhancement Endoscopy
Interventions
Device: first WLI
Device: first OE
First Posted Date
2018-10-09
Last Posted Date
2018-10-09
Lead Sponsor
Shandong University
Target Recruit Count
214
Registration Number
NCT03700398
Locations
🇨🇳

Qilu Hospital of Shandong University, Jinan, Shandong, China

Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus

Phase 2
Conditions
Esophagus Squamous Cell Carcinoma
Interventions
First Posted Date
2018-07-13
Last Posted Date
2021-04-06
Lead Sponsor
Huai'an First People's Hospital
Target Recruit Count
32
Registration Number
NCT03585530
Locations
🇨🇳

Huai'an First Hospital, Huai'an, Jiangsu, China

Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma

Phase 2
Conditions
Esophagus Squamous Cell Carcinoma (SCC)
Metastatic Cancer
Interventions
Drug: Docetaxel-PM
Drug: Oxaliplatin
First Posted Date
2018-07-13
Last Posted Date
2018-07-17
Lead Sponsor
Sung Yong Oh
Target Recruit Count
38
Registration Number
NCT03585673
Locations
🇰🇷

Dong-A University Hospital, Busan, Korea, Republic of

Association Between VEGF-C and miRNA and Clinical Non-small Cell Lung Cancer and Esophagus Squamous Cell Carcinoma

Conditions
VEGFC Protein in ESCC
VEGFC Protein in Serum
VEGFC Protein in Non Small Cell Lung Cancer
CTTN Protein in ESCC
miR326 in ESCC and Non Small Cell Lung Cancer
First Posted Date
2010-11-15
Last Posted Date
2010-11-15
Lead Sponsor
China Medical University Hospital
Target Recruit Count
250
Registration Number
NCT01240369
© Copyright 2025. All Rights Reserved by MedPath